Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

NCT03255018 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

NIH

Sponsor class

Conditions

Non-Hodgkin Lymphoma
Lymphoma
Diffuse Large B-Cell Lymphoma
Gray-zone Lymphoma
Primary Central Nervous System Lymphoma

Interventions

BIOLOGICAL: Pembrolizumab

Sponsor

National Cancer Institute (NCI)